Intellia Therapeutics Inc. (38I)
Summary
38I Chart
NTLA Q2 Earnings In Line, Top Line Misses on Lower Regeneron Revenues
Intellia's Q2 loss matches estimates, but revenues fall 46.2% as lower Regeneron collaboration revenues weigh on results.
Intellia Therapeutics Q2 Earnings Call Highlights
Intellia Therapeutics NASDAQ: NTLA said it advanced its lead gene-editing programs during the second quarter, highlighting positive Phase III results for lonvo-z in hereditary angioedema and the resumption of enrollment in Phase III studies of nex-z for transthyretin amyloidosis.
Intellia Therapeutics, Inc. (NTLA) Reports Q2 Loss, Lags Revenue Estimates
Intellia Therapeutics, Inc. (NTLA) came out with a quarterly loss of $0.8 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.99 per share a year ago.
Intellia Therapeutics Inc. (38I) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Intellia Therapeutics Inc. ever had a stock split?
Intellia Therapeutics Inc. Profile
| Biotechnology Industry | Healthcare Sector | John Leonard CEO | XSTU Exchange | 45826J105 CUSIP |
| US Country | 377 Employees | - Last Dividend | - Last Split | 6 May 2016 IPO Date |
Overview
Intellia Therapeutics, Inc., established in 2014 and based in Cambridge, Massachusetts, represents a pioneering force in the biotechnology industry, focusing on the advancement of genome editing technology to create curative treatments. With a strategic emphasis on the development of therapeutics through the CRISPR/Cas9 system, Intellia aims to address a variety of genetic diseases and conditions. The company's collaborative approach involves partnerships with leaders in the pharmaceutical and biotech sectors, such as Regeneron Pharmaceuticals, Inc., AvenCell Therapeutics, Inc., SparingVision SAS, Kyverna Therapeutics, Inc., and ONK Therapeutics, Ltd., to fuel the development of innovative therapies.
Products and Services
- NTLA-2001
Currently in Phase 1 clinical trials, NTLA-2001 targets transthyretin amyloidosis, aiming to provide a groundbreaking treatment option for this condition.
- NTLA-2002
NTLA-2002 is under development for hereditary angioedema, showcasing Intellia's commitment to tackling rare genetic disorders.
- NTLA-3001
This program focuses on treating alpha-1 antitrypsin deficiency associated lung disease, underlining the company's efforts in addressing respiratory conditions with a genetic foundation.
- Hemophilia A and B
In partnership with Regeneron Pharmaceuticals, Inc., Intellia is co-developing potential products aimed at treating hemophilia A and B, further expanding their portfolio in genetic disease treatment.
- Engineered Cell Therapies for Cancer and Autoimmune Diseases
Intellia is also exploring the research and development of proprietary programs focused on engineered cell therapies. These are intended to treat various cancers and autoimmune diseases, illustrating a versatile approach in applying genome editing.
- CRISPR/Cas9 Technology for Ocular Diseases
Through its collaboration with SparingVision SAS, Intellia aims to develop novel genomic medicines utilizing CRISPR/Cas9 technology to combat ocular diseases.
- Allogeneic Universal CAR-T Cell Therapies
Working alongside AvenCell Therapeutics, Inc., and Kyverna Therapeutics, Inc., Intellia is set on developing allogeneic universal CAR-T cell therapies. These efforts signify a leap forward in immuno-oncology, targeting B cell-mediated autoimmune diseases and various cancers.
- Engineered NK Cell Therapies
In collaboration with ONK Therapeutics, Ltd., Intellia is focused on the development of engineered NK cell therapies, aiming to provide curative treatments for patients suffering from cancer.
